NITI Aayog holds first National Workshop on 'Leadership as a Mission' (See 'Corp Brief') MISC - Resolution Plan has been approved under the IBC - No further adjudication is required in the present writ petition: HC (See 'Legal Desk') IEPFA and SEBI to Organize 'Niveshak Shivir' in New Delhi (See 'Corp Brief') Ministry of Power Pavilion showcases Power Sector Initiatives at IIFT (See 'Corp Brief') MY Bharat mobilises over 81,600 youth and citizens through Sports Meets (See 'Corp Brief') 12th Session of India-Belarus Inter-Governmental Commission held in New Delhi (See 'Corp Brief') CPC/Limitation - Entries in books of account & balance sheets can constitute acknowledgment of liability u/s 18 of Limitation Act, provided they indicate subsisting jural relationship when read with surrounding circumstances: SC LB (See 'Legal Desk') India to host Ministerial Meeting of International Coconut Community in Kochi (See 'Corp Brief') India Post releases Commemorative Postage Stamp on Pioneer of Biogas Technology (See 'Corp Brief') NICDC Pavilion showcases AP's Greenfield Industrial Smart Cities (See 'Corp Brief') CCPA imposes Penalty of Rs 20 Lakh on ExportersIndia.com (See 'Corp Brief') IBC - RP required to function independently & cannot act according to whims & fancies of a dominant Financial Creditor - CoC's majority decision to replace RP cannot be interfered with by another Financial Creditor holding minority voting share: NCLAT (See 'Legal Desk') IITF 2026 - EPFO Lounge & ESIC Pavilion inaugurated (See 'Corp Brief') Giriraj Singh visits Welspun World's State-of-the-Art Manufacturing Units in Kutch (See 'Corp Brief') PMLA - Status of secured creditor & initiation of prior recovery proceedings under SARFAESI Act do not exempt a property from attachment under PMLA, when property constitutes proceeds of crime: SAFEMA Tribunal (See 'Legal Desk') Indian Business leaders and Start ups to participate in the India-Egypt Business Forum (See 'Corp Brief') NRIDA selected for Medal for Innovation in Road Technology (See 'Corp Brief') PMLA - Objectives of special anti-money laundering law supersede private commercial security interests - properties linked to criminal activities liable to provisional & final attachment: SAFEMA Tribunal (See 'Legal Desk') Shilp Samagam Mela 2026 at Dilli Haat records Cumulative Sales of Over Rs 88.36 Lakh (See 'Corp Brief') National Tribal Literary Festival concludes with Emphasis on Preserving Oral Traditions (See 'Corp Brief') SEBI - Freezing the Appellants' demat & bank accounts pending deposit of alleged unlawful gains of Rs. 28.12 crore, is valid: SAT (See 'Legal Desk') An unsuccessful 'success fee' litigation (See CORP EINSICHT)

CCI olays 20% equity buy of Piramal Pharma by Clover Investments

Published: Sep 12, 2020

By TIOLCORPLAWS News Service

NEW DELHI, SEPT 12, 2020: The Competition Commission of India (CCI) approves proposed combination involving acquisition of 20% of the issued and paid-up equity share capital of Piramal Pharma Limited (Pharma Co.) by CA Clover Intermediate II Investments (Curie).

The proposed combination relates to (i) the transfer of global pharmaceutical business ( Transferred Business ) by Piramal Enterprises Limited ( PEL ) to a wholly owned subsidiary of PEL, i.e. Pharma Co., followed by, (ii) the acquisition of 20% of the issued and paid-up equity share capital of Pharma Co. by Curie ( Proposed Combination ).

Curie is a special purpose acquisition vehicle, owned and controlled by investment funds advised by the affiliates of the Carlyle Group Inc. (“ Carlyle Group ”).

The Carlyle Group is a global alternative asset manager, which manages funds that invest globally across four investment disciplines: (i) Corporate Private Equity (buyout and growth capital), (ii) Real Assets (real estate, infrastructure and energy and renewable resources), (iii) Global Credit (leveraged loans and structured credit, opportunistic credit, energy credit, private credit and distressed credit), and (iv) Solutions (private equity fund of funds program and related co-investment and secondary activities).

Pharma Co. is a wholly owned entity of PEL that will hold PEL's Transferred Business as part of the Proposed Combination, and acquire the pharmaceutical business of PEL comprising the Contract Development and Manufacturing Organisation ( CDMO ), Complex Hospital Generics ( CHG ), and Consumer Healthcare Division ( CHD )segments, as well as equity interest in certain PEL entities.

TIOL CORP SEARCH

TIOL GROUP WEBSITES